Incretin Franchise Drives 56% Revenue Growth, Prompting $2 Billion Increase to Full-Year Guidance FY2026 Q1 | May 28, 2026

FY26 Guidance Projects 25% Revenue Growth, Navigating a 'Low to Mid-Teens' Price Headwind Through Volume Expansion FY2025 Q4 | Feb 04, 2026

Orforglipron Advances to Submission Following 54% Revenue Growth; FY2025 Outlook Raised on Incretin Momentum FY2025 Q3 | Nov 03, 2025

Pivotal Phase 3 Successes for Orforglipron and Tirzepatide Drive Significant Raise to FY2025 Revenue and EPS Guidance FY2025 Q2 | Sep 18, 2025

Orforglipron Phase 3 Success Validates Oral GLP-1 Strategy as U.S. Manufacturing Investment Doubles to Over $50B FY2025 Q1 | Sep 18, 2025

Incretin Franchise Drives 45% Revenue Growth as Supply Stabilizes; 2025 Guidance Projects Over 30% Growth FY2024 Q4 | Sep 18, 2025

Incretin Sales Navigate Channel Destocking as Company Pivots to Full Commercial Launch, Signaling ~50% Revenue Growth in Q4 FY2024 Q3 | Sep 18, 2025

Manufacturing Scale-Up Fuels Incretin Momentum, Prompting $3 Billion Full-Year Revenue Guidance Increase FY2024 Q2 | Sep 18, 2025

Incretin Sales Surge Prompts $2B Revenue Guidance Increase as Manufacturing Confidence Grows FY2024 Q1 | Sep 18, 2025

Mounjaro and Zepbound Propel 28% Revenue Growth; Company Forecasts Demand to Outpace Supply in 2024 FY2023 Q4 | Sep 18, 2025

Underlying Revenue Growth Accelerates to 24%; EPS Guidance Cut on $3B in Acquired IPR&D Charges FY2023 Q3 | Sep 18, 2025

Mounjaro Powers 22% Core Revenue Growth; Full-Year Guidance Raised by $2.2 Billion FY2023 Q2 | Sep 17, 2025

Incretin Franchise Powers 10% Core Revenue Growth and Raised FY23 Outlook Amid Imminent Obesity Filing FY2023 Q1 | Sep 17, 2025

Sign in required

dbot

Eli Lilly and Company - Reports